NLRP3 and polycystic ovary syndrome: Therapeutic strategies targeting the inflammation–oxidative stress axis in PCOS include MET, which activates AMPK, inhibits NF-κB p65 phosphorylation at Ser536, and prevents NLRP3 inflammasome formation by downregulating TXNIP.